Infliximab Level and Ab

Test investigation

Infliximab Level and Ab

Laboratory offering test

Referral laboratory

Units

µg/mL

Also known as/Frequency of test

Remicade; Remsima; Inflectra, ADA – Anti-Drug antibodies

Indications

Diseases such as ulcerative colitis and Crohn’s disease respond to anti-Tumour Necrosis Factor alpha (TNF-α) therapy (e.g. Adalimumab/ infliximab). During treatment some patients can generate high levels of anti-drug antibodies (ADAs) which negate therapeutic effect. The serum concentration of the drug immediately prior to re-infusion (trough level) is needed to interpret the relevance of ADAs. Please refer to specialty guidelines for monitoring.

Sample type

Serum

Turnaround times (TAT) Urgent/Routine/GP or OPD

2 weeks

Reference intervals

>2.0 µg/mL Therapeutic values for Adalimumab (or biosimilar) vary according to pathology